secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001104659-26-026439
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance
--------------------------------------------------------------------------------

- Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.
- Nasdaq granted additional 180 calendar days, until September 7, 2026, to cure deficiency.
- VYNE may consider a reverse stock split to meet the bid price requirement.
- Common stock continues trading on Nasdaq Capital Market under symbol VYNE during extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/0001104659-26-026439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/tm268461d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-026439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer